» Articles » PMID: 1702714

Enzymatic Activity of Prostate-specific Antigen and Its Reactions with Extracellular Serine Proteinase Inhibitors

Overview
Journal Eur J Biochem
Specialty Biochemistry
Date 1990 Dec 27
PMID 1702714
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate-specific antigen (PSA) is one of the three most abundant prostatic-secreted proteins in human semen. It is a serine proteinase that, in its primary structure, manifests extensive similarities with that of the Arg-restricted glandular kallikrein-like proteinases. When isolated from semen by the addition of chromatography on aprotinin-Sepharose to a previously described procedure, PSA displayed chymotrypsin-like activity and cleaved semenogelin and the semenogelin-related proteins in a rapid and characteristic pattern, but had no trypsin-like activity. About one third of the purified protein was found to be enzymatically inactive, due to cleavage carboxy-terminal of Lys145. Active PSA formed SDS-stable complexes with alpha 1-antichymotrypsin, alpha 2-macroglobulin-analogue pregnancy zone protein. PSA formed inhibitory complexes with alpha 1-antichymotrypsin at a molar ratio of 1:1, a reaction in which PSA cleaved the inhibitor in a position identical to that reported from the reaction between chymotrypsin and alpha 1-antichymotrypsin. The formation of stable complexes between PSA and alpha 1-antichymotrypsin occurred at a much slower rate than that between chymotrypsin and alpha 1-antichymotrypsin, and at a similar or slightly slower rate than that between PSA and alpha 2-macroglobulin. When added to normal blood plasma in vitro, active PSA formed stable complexes both with alpha 2-macroglobulin and alpha 1-antichymotrypsin. This complex formation may be a crucial determinant of the turnover of active PSA in intercellular fluid or blood plasma in vivo.

Citing Articles

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.

PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.


Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment.

Tu Y, Gong J, Mou J, Jiang H, Zhao H, Gao J Front Pharmacol. 2024; 15:1434137.

PMID: 39144632 PMC: 11322083. DOI: 10.3389/fphar.2024.1434137.


Designed ankyrin repeat proteins for detecting prostate-specific antigen expression .

Gut M, Dreier B, Furler S, Sobek J, Pluckthun A, Holland J RSC Chem Biol. 2023; 4(7):494-505.

PMID: 37415866 PMC: 10320840. DOI: 10.1039/d3cb00010a.


The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.

El-Magid A, AbdEl-Hamid O, Younes M Biol Trace Elem Res. 2022; 201(4):1935-1945.

PMID: 35689758 PMC: 9931816. DOI: 10.1007/s12011-022-03298-0.


Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options.

Narain T, Sooriakumaran P World J Mens Health. 2022; 40(1):66-73.

PMID: 34983086 PMC: 8761236. DOI: 10.5534/wjmh.210076.